Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lalitendu Mohanty"'
Autor:
Lalitendu Mohanty, T. Jacob John, Shailesh D. Pawar, Padmasani Venkat Ramanan, Sharad Agarkhedkar, Pradeep Haldar
Publikováno v:
Vaccines, Vol 12, Iss 4, p 424 (2024)
Background: In 2016, the Global Polio Eradication Initiative (GPEI) recommended the cessation of using type 2 oral poliovirus vaccine (OPV) and OPV, with countries having to switch from the trivalent to bivalent OPV (bOPV) with the addition of inacti
Externí odkaz:
https://doaj.org/article/8c70d2cdfd5c4563ae379bc9ebf3b422
Autor:
Lalitendu Mohanty, Madhav Prabhu, Amit Kumar Mishra, Anil J Purty, Reba Kanungo, Goutam Ghosh, R Prahan Kumar, A. Newton Raj, Sumit Bhushan, Manoj Kumar Jangir, Anu Gupta, Anju Bhakri
Publikováno v:
Vaccine: X, Vol 10, Iss , Pp 100142- (2022)
Background: Dengue fever is the most prevalent mosquito-borne viral disease in the world, with 390 million dengue infections occurring every year. There is an unmet medical need to develop a safe, effective and affordable dengue vaccine against all f
Externí odkaz:
https://doaj.org/article/7341c803fd8e4d1084aaf49dfd931348
Autor:
Lalitendu Mohanty, Sunil Sharma, Beauty Behera, Sachin Panwar, Charu Paliwal, Anit Singh, Anu Gupta, Deepak Chandra Chilkoti
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 9, Pp 2025-2031 (2017)
An open-label, randomized, multi-center trial was conducted to compare the immunogenicity and safety of an indigenously developed tetravalent DTwP-Hib vaccine, Easyfour®-TT with a commercially available vaccine, Quadrovax®. A total of 244 infants i
Externí odkaz:
https://doaj.org/article/8d92ed93d96c45cdbdac49d86a14e5af
Autor:
Manish Jain, Balasundaram Krishnamurthy, Jagadish Deshpande, Harish Verma, Mohammad Ahmad, Raman Sethi, Ashish Bavdekar, Lalitendu Mohanty, Abhishek Kunwar, Niranjana S Mahantashetti, Deepa Sharma, Jayaseelan Visalakshi, Sunil Bahl, Shailesh D. Pawar, Mannancheril A Mathew, Pradeep Haldar, Roland W. Sutter
Publikováno v:
Journal of the Pediatric Infectious Diseases Society. 11:60-68
Introduction Following the withdrawal of Sabin type 2 from trivalent oral poliovirus vaccine (tOPV) in 2016, the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV) in routine immunization was recommended, either as 1 full dose (0.5mL,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b05eab4d92fdaa365748e10449f1f955
https://doi.org/10.1093/jpids/piab091
https://doi.org/10.1093/jpids/piab091
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective The present study compared the pharmacokinetics of two (1 mg) tacrolimus formulations (test (generic from Panacea) and reference (innovator from Astellas)) after a single-dose administration as per the European Medicine Agency (EMA) guideli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d74eacdc54391f6c91e5b2456ae9753e
http://europepmc.org/articles/PMC7041308
http://europepmc.org/articles/PMC7041308
Autor:
Anu Gupta, Anit Singh, Sachin Panwar, Charu Paliwal, Lalitendu Mohanty, Sunil Sharma, Deepak Chandra Chilkoti, Beauty Behera
Publikováno v:
Vaccine. 36(17)
Immunogenicity and safety of a newly developed liquid DTwP-Hib/HepB-IPV hexavalent vaccine (EasySix™) was evaluated and compared with administration of commercially licensed Pentavac SD® (DTwP-HepB/Hib) and Imovax Polio® vaccine in an open-label,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a07ae9919cac4abdb1aa02c6acec4882
https://pubmed.ncbi.nlm.nih.gov/29580640
https://pubmed.ncbi.nlm.nih.gov/29580640